" class="no-js "lang="en-US"> Eisai - Medtech Alert
Thursday, October 03, 2024
Eisai | MTA

Eisai

About Eisai

Eisai
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina.

Related Story

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain

May 22 2023

Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]

Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701

May 8 2023

Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]

U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease

March 14 2023

BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

February 28 2023

Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]